CTRI/2022/11/047591
Completed
Phase 4
A single-arm, multicentric, open-label clinical study to evaluate the efficacy and safety of â??Nimulid Strong Gel (Diclofenac Diethylamine, Methyl Salicylate, and Menthol)â?? topical analgesic gel in subject suffering from pain associated with recent muscle or joint injuries such as sprains, strains, or sports injuries.
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Health Condition 1: M959- Acquired deformity of musculoskeletal system, unspecified
- Sponsor
- Mankind Pharma Limited
- Enrollment
- 60
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Male or Female subject age between 18\-65 years (both inclusive)
- •2\) Subject suffering from pain associated with recent muscle or joint injuries such as sprains, strains, or sports injuries within 24 hours of
- •3\) Pain Intensity score of \>\=5 on an 11\-point NRS, at rest or during movement unilateral grade I or II acute sprain.
- •4\) Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.
- •5\) Females of childbearing potential, using an effective contraceptive method for at least one month before the beginning of the study, and willing to use throughout the study.
Exclusion Criteria
- •1\) Subject has treated the pain with treatment such as oral or other topical pain relief medications, massage or physical therapy since experiencing the sprain, strains, or sports injuries.
- •2\) Acute or chronic pain disorders, which may confound the study pain evaluations
- •3\) Subject noted to have grade III sprain or fracture
- •4\) Subjects having recent history (within one year) of alcohol or other substance abuse as
- •determined by medical history.
- •5\) More than one injuries on same limb.
- •6\) Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit.
- •7\) Previous participation in similar study with similar products within 30 days.
- •8\) Subject has any visible skin disease at the site of application that, in the opinion of the
- •investigator, will interfere with the skin assessments.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A study comparing the use of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects with Rheumatoid ArthritisEUCTR2014-004887-39-PLSamsung Bioepis Co., Ltd
Active, not recruiting
Not Applicable
A study to assess the safety and effectiveness of toothpaste in human subjects with diabetesHealth Condition 1: E089- Diabetes mellitus due to underlying condition without complicationsHealth Condition 2: K056- Periodontal disease, unspecifiedCTRI/2023/09/057700Himalaya Wellness Company
Unknown
Phase 3
Clinical trial to determine the efficacy and tolerability of oral iron preparations in iron deficiency aneamia in pregnancyCTRI/2021/07/035277GC Chemie Pharmie Ltd4
Completed
Not Applicable
Anti-Dandruff Shampoo Testing on healthy male and females adult subjects.CTRI/2021/06/033998The Himalaya Drug Company99
Completed
Not Applicable
Anti-Dandruff Shampoo Testing on healthy male and females adult subjects.CTRI/2021/06/034226The Himalaya Drug Company102